CHMP recommends Merck's Keytruda for urothelial carcinoma

EMA's CHMP recommended a label expansion for Keytruda pembrolizumab (MK-3475) from Merck & Co. Inc. (NYSE:MRK) to include locally advanced or metastatic urothelial carcinoma in patients who have received prior platinum-containing chemotherapy or who are not eligible for cisplatin-containing chemotherapy...